New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 25, 2013
10:11 EDTABAX, BP, PLCE, DVAX, TGP, CBSH, ALU, OC, TEVA, HNZ, DEPO, PETM, ARO, ASNA, BRY, ENDP, GLF, NBL, NVE, SM, TDW, WPZOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Abaxis (ABAX) downgraded to Underperform from Neutral at BofA/Merrill... Aeropostale (ARO) downgraded to Hold from Buy at KeyBanc... Affymax (AFFY) downgraded to Neutral from Outperform at RW Baird... Ascena Retail (ASNA) downgraded to Hold from Buy at KeyBanc... Berry Petroleum (BRY) downgraded to Neutral from Positive at Susquehanna... Endo Health (ENDP) downgraded to Underweight from Neutral at Piper Jaffray... GulfMark Offshore (GLF) downgraded to Buy from Strong Buy at ISI Group... NV Energy (NVE) downgraded to Hold from Buy at Wunderlich... Noble Energy (NBL) downgraded to Buy from Conviction Buy at Goldman... SM Energy (SM) downgraded to Market Perform from Outperform at BMO Capital... Tidewater (TDW) downgraded to Neutral from Buy at ISI Group... PetSmart (PETM) downgraded to Equal Weight from Overweight at Johnson Rice... Depomed (DEPO) downgraded to Hold from Buy at WallachBeth... BP (BP) downgraded to Buy from Strong Buy at ISI Group... Children's Place (PLCE) downgraded at Janney Capital... Dynavax (DVAX) downgraded to Hold from Buy at MLV Equity... Teekay LNG (TGP) downgraded at Raymond James... Commerce Bancshares (CBSH) downgraded at Raymond James... Alcatel-Lucent (ALU) downgraded to Underweight from Neutral at HSBC... Teva (TEVA) downgraded to Hold from Buy at Argus... Owens Corning (OC) downgraded to Market Perform from Outperform at Wells Fargo... Heinz (HNZ) downgraded to Neutral from Buy at Citigroup... Williams Partners (WPZ) downgraded to Accumulate from Buy at Global Hunter.
News For ABAX;ARO;ASNA;BRY;ENDP;GLF;NBL;NVE;SM;TDW;PETM;DEPO;BP;PLCE;DVAX;TGP;CBSH;ALU;OC;TEVA;HNZ;WPZ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
October 12, 2014
13:53 EDTBPKuwaiti Minister says OPEC unlikely to cut production, WSJ says
Subscribe for More Information
13:45 EDTBPSaudis take aggressive oil measures in Europe, WSJ says
Subscribe for More Information
October 10, 2014
11:49 EDTASNAAscena Retail management to meet with Oppenheimer
Subscribe for More Information
10:01 EDTENDPOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:05 EDTBPBP begins $1.1B North Sea project, Bloomberg says
BP CEO Bob Dudley said that the company is poised to begin a project worth close to $1.1B in the North Sea this month, which is anticipated to supply oil and gas into the next ten years, according to Bloomberg, citing comments from Dudley. Reference Link
05:50 EDTENDPEndo upgraded to Overweight from Neutral at Piper Jaffray
Piper Jaffray upgraded Endo (ENDP) to Overweight with an $84 price target citing an improved asset base following the takeover of Auxilium (AUXL).
05:47 EDTENDPAuxilium downgraded to Neutral from Buy at Mizuho
Mizuho downgraded Auxilium (AUXL) to Neutral following the company's agreement to be acquired by Endo (ENDP). The firm expects shareholders to approve the deal and does not expect a competing bid.
October 9, 2014
18:02 EDTSMSM Energy sees Q3 production at lower end of previous guidance range
Subscribe for More Information
16:11 EDTTEVAAlexza reports 32,278 Adasuve units shipped to Teva in Q3
Subscribe for More Information
10:55 EDTALUAlcatel-Lucent upgraded to Buy from Hold at Craig-Hallum
Subscribe for More Information
09:41 EDTAROBofA/Merrill retail analysts hold an analyst/industry conference call
Subscribe for More Information
09:20 EDTENDPOn The Fly: Pre-market Movers
Subscribe for More Information
09:00 EDTENDPEndo says its not in position to give FY15
Subscribe for More Information
08:49 EDTENDPEndo sees low-double digit revenue growth with Auxilium portfolio
Subscribe for More Information
08:37 EDTENDPEndo expects Auxilium acquisition immediately accretive post close
Endo (ENDP) says the deal will provided expected annual run rate synergies of up to $175M by the first year after closing versus Auxilium's (AUXL trailing 12-month actuals as of June 30. Says synergies include Auxilium's $75M reduction in annual operating expenses previously announced. Says the deal is expected to "significantly'" enhance Endo's branded pharmaceutical business with the addition of Auxilium's men's health products and development portfolio. Says the agreement is designed to "accelerate growth" and maximize value of Auxilium's products by leveraging strengths of combined company. Says combined company will be "well positioned" to drive organic growth for branded pharmaceutical business. Says deal creates a "strong" margin profile and an enhanced near-and long-term revenue growth profile. Comments taken from the company's slide presentation regarding its combination with Auxilium.
07:49 EDTENDPEndo and Auxilium host a joint conference call
Subscribe for More Information
06:32 EDTENDPEndo to acquire Auxilium in cash, stock transaction for approximately $2.6B
Endo (ENDP) and Auxilium Pharmaceuticals (AUXL) announced that they have entered into a definitive agreement under which Endo will acquire all of the outstanding shares of common stock of Auxilium for a per share consideration of $33.25 in a cash and stock transaction. The boards of both companies have unanimously approved the transaction, which is valued at $2.6B, including the repayment and assumption of debt. The transaction will include an election mechanism for Auxilium stockholders to elect cash and stock, all-stock or all-cash consideration, subject to proration in accordance with the terms of the definitive agreement. The per share consideration represents a premium of 55% to Auxilium's closing price on September 16, the day Endo made public its proposal for Auxilium. Subject to aggregate cash and equity consideration limits, Auxilium stockholders may elect one of three options with respect to transaction consideration: 100% equity which equates to 0.488 Endo shares per Auxilium share, 100% cash which equates to $33.25 per Auxilium share or a standard election of an equal mix of $16.625 in cash and 0.244 Endo shares per Auxilium share. The total cash consideration will not exceed 50% of the total equity value and the equity consideration will not exceed 75% of the total equity value. The transaction is expected to close in 1H15 and is subject to the approval of Auxilium's stockholders, regulatory approval in the U.S. and certain other jurisdictions, and other customary closing conditions.
06:31 EDTENDPEndo to acquire Auxilium in cash, stock transaction for approximately $2.6B
Subscribe for More Information
October 8, 2014
08:05 EDTTEVATeva initiates NDA submission to FDA for CEP-33237
Teva Pharmaceutical announced the initiation of a rolling New Drug Application submission to the U.S. Food and Drug Administration for hydrocodone bitartrate extended-release tablets designed with Teva’s proprietary technology providing potential abuse-deterrent properties CEP-33237 as allowed for fast track designated products. Teva expects to complete the NDA submission by the end of 2014. Teva also announced positive results from a nasal Human Abuse Liability study which supports the NDA. The nasal HAL study found that in nondependent, recreational opioid users, abuse potential for crushed intranasal CEP-33237 was significantly lower than intranasal immediate-release hydrocodone. Teva has now completed positive HAL studies in the two most common routes of hydrocodone abuse, oral and intranasal. CEP-33237 demonstrated a safety profile in the Phase III study that is consistent with the known safety profile of hydrocodone and other opioid analgesic therapies. Adverse events reported in 5% or more of hydrocodone-treated patients during either the titration or double-blind treatment periods included nausea, constipation, vomiting, headache, somnolence and dizziness.
06:47 EDTTEVALawmakers may push for new regulations on generic drug makers, NY Times says
After the prices of some generic drugs soared more than 1,000% over the last year, two influential members of Congress are probing the sector and threatening to look to impose new regulations on it, according to The New York Times. Generic drug makers include Teva (TEVA), Mylan (MYL), Actavis (ACT), and Lannett (LCI).Reference Link
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use